MindBio Therapeutics

MindBio Therapeutics is a clinical stage drug development company that is pioneering psychedelic microdosing in multiple Phase 2B clinical trials. MB22001 is MindBio's lead candidate drug, a proprietary titratable form of Lysergic Acid Diethylamide (LSD) designed for safe take home microdosing. Phase 2 clinical trials are underway. Clinical trials include: 1. Phase 2B trial in patients with Major Depressive Disorder 2. Phase 2B trial in patients with Late Stage Cancer and Depression The Phase 2B trial in patients with Major Depressive Disorder will evaluate the effectiveness of MB22001 in treating depression. We know from an open label Phase 2A trial in 20 patients with Major Depressive Disorder, that 53% of patients with depression were in complete remission from their depression at week 8. This is represented by a 14.1 point drop in MADRS score (Montgomery-Asberg Depression Rating Scale). The 60% overall improvement in depressive symptoms and previous successful trials in healthy individuals gives the company confidence going into Phase 2B trials that MB22001 is a very promising treatment for Depression. The Phase 2 clinical trials for cancer patients will evaluate the feasibility of conducting a randomised controlled trial comparing psychedelic-microdose assisted – Meaning Centred Psychotherapy to standard Meaning-Centred Psychotherapy in people who have advanced cancer and anxiety or depression. Participants will be randomised to receive psychotherapy alongside doses of either an LSD microdose or placebo. The feasibility, acceptability, safety and potential psychological benefits of this intervention will be assessed. Our findings will inform the development of a larger trial and provide initial indication of potential benefits of psychedelic microdosing in advanced cancer.